Hepatitis E is receiving greater attention across healthcare systems as clinicians increasingly recognise that unexplained liver inflammation can involve infections that are not routinely investigated during initial diagnosis. Improvements in laboratory testing, growing awareness of transfusion-associated infections and the need to identify high-risk patients are bringing hepatitis E diagnostics into sharper focus. The evolution of this market is closely connected to how quickly healthcare providers can distinguish HEV infection from other liver diseases and confirm active viral replication.
Hepatitis E Diagnostic Tests Market encompasses antibody-based assays, enzyme-linked immunosorbent assays (ELISA), rapid diagnostic tests and molecular techniques such as reverse transcription polymerase chain reaction (RT-PCR). Their applications extend across hospitals, diagnostic laboratories, blood banks, transplant centres and public health surveillance programmes.
The Overlooked Infection behind Unexplained Liver Inflammation
-
Hepatitis E is no longer viewed exclusively as an infection associated with contaminated drinking water and developing countries.
-
Although waterborne transmission remains important, zoonotic transmission through contaminated or insufficiently cooked animal products is also recognised, particularly in parts of Europe.
-
The World Health Organization estimates that approximately 20 million HEV infections occur globally each year, resulting in around 3.3 million symptomatic cases.
-
The disease caused approximately 4,431 deaths in 2023. These figures demonstrate why diagnostic identification remains important even when symptoms initially resemble other forms of viral hepatitis.
-
For healthcare providers, the difficulty is that fatigue, nausea, abdominal discomfort and jaundice do not independently establish HEV infection.
-
Consequently, laboratory confirmation becomes essential when conventional hepatitis investigations fail to explain abnormal liver function.
ELISA and IgM Testing Remain Important in Clinical Investigations
Serological testing continues to provide an accessible starting point for identifying hepatitis E. Anti-HEV IgM assays help identify recent infection, whereas IgG testing provides information about previous exposure.
ELISA-based testing is particularly relevant in hospital laboratories because it can process multiple patient specimens within a single testing workflow. This makes it useful for clinical investigations and suspected outbreak assessments.
-
However, antibody detection is not equally reliable in every patient. Differences between commercial assay performance, timing of specimen collection and individual immune responses can influence results. Therefore, clinicians may require additional testing when antibody findings do not correspond with the patient's clinical condition.
RT-PCR Brings Greater Attention to Active Viral Detection
Molecular diagnostics are becoming increasingly important when healthcare professionals need to establish whether HEV genetic material is present in blood or stool specimens.
-
Real-time RT-PCR can identify viral RNA, supporting the confirmation of active infection. This approach is particularly valuable for immunocompromised patients, including organ transplant recipients, because their antibody responses may be insufficient for dependable serological diagnosis.
-
The World Health Organization includes hepatitis E nucleic acid amplification testing in its Model List of Essential In Vitro Diagnostics. Its inclusion reflects the clinical importance of molecular confirmation and the need to make appropriate testing available through laboratory networks.
Another important development involves international assay standardisation. In 2025, the WHO considered a proposal for a second international reference standard for HEV RNA testing. The initiative is relevant to laboratories seeking greater consistency when comparing molecular results across diagnostic platforms.
For a more thorough report, please contact us using our most recent report: https://www.24lifesciences.com/hepatitis-e-diagnostic-tests-market-9474
Blood Transfusion Safety Is Creating a Different Testing Requirement
One of the most important developments in hepatitis E diagnostics concerns blood donation screening. HEV can remain undetected in apparently healthy donors, creating a potential transmission pathway through blood components.
In December 2025, the UK's Advisory Committee on the Safety of Blood, Tissues and Organs published a review examining the effectiveness of existing HEV screening practices. The assessment considered nucleic acid testing of blood and platelet donations, including pooled testing approaches involving 16 or 24 donations.
This development highlights an important distinction between conventional patient diagnosis and blood-bank screening. Hospitals generally investigate suspected infection, whereas transfusion services must consider infections that donors may not know they have.
For diagnostic manufacturers, this creates demand for assays that can support high-volume screening, reliable RNA detection and efficient laboratory workflows.
Pregnancy and Transplant Medicine Require Greater Diagnostic Attention
Hepatitis E testing has particular clinical importance in maternal healthcare. Infection during pregnancy, especially during the second and third trimesters, can lead to severe complications, including acute liver failure and fetal loss. WHO reports that mortality among infected pregnant women can reach 20-25% during the third trimester.
Transplant medicine represents another important application. Immunosuppressive treatment can allow HEV infection to persist, occasionally progressing into chronic hepatitis. In these circumstances, repeated RNA testing can help clinicians monitor infection rather than relying exclusively on antibody results.
These clinical requirements are encouraging closer integration between hepatology, infectious disease specialists, obstetricians and specialised diagnostic laboratories.
India's Diagnostic Landscape and the Importance of Laboratory Access
-
India remains an important healthcare setting for hepatitis E diagnosis because waterborne outbreaks, sanitation conditions and population-level exposure continue to influence public health requirements.
-
The country's National Guidelines for Diagnosis and Management of Viral Hepatitis recognise anti-HEV IgM detection as an important laboratory approach for confirming infection.
-
However, access to specialised molecular testing remains relevant when clinical findings are inconclusive or unusual infection patterns require further investigation.
-
Expanding laboratory capacity, improving specimen transportation and strengthening referral networks can help smaller healthcare facilities access more specialised diagnostic services.
What the Next Generation of HEV Testing Needs to Deliver?
The next phase of Hepatitis E Diagnostic Tests Market will depend on more than introducing additional assay formats. Healthcare providers increasingly need diagnostic solutions that combine dependable results, practical turnaround times and compatibility with established laboratory infrastructure.
Rapid testing can support preliminary investigations in settings with limited laboratory facilities, while molecular assays remain important for confirming active infection and investigating complicated cases.
Greater standardisation, improved diagnostic accessibility and stronger integration with blood safety programmes will shape the practical relevance of these technologies. Ultimately, the value of hepatitis E diagnostics lies in identifying infections that might otherwise remain unexplained, overlooked or incorrectly classified as other liver conditions.
Authoritative Sources and Further Reading
World Health Organization (WHO) - Hepatitis E: Global Disease Burden, Diagnosis and Prevention.
WHO Essential Diagnostics List - Hepatitis E Virus Nucleic Acid Amplification Testing.
UK Government - Hepatitis E Virus Transmission by Blood Transfusion: Screening Effectiveness Review, December 2025.
Ministry of Health and Family Welfare, Government of India - National Guidelines for Diagnosis and Management of Viral Hepatitis.
European Centre for Disease Prevention and Control (ECDC) - Hepatitis E: Diagnostic Methods and Disease Information
